Patient-Centered, Continuous Care.
Patients are placing new expectations on health systems for greater care personalization. Our model of continuous care delivers, with no added burden to patients or the health care system.
Their Devices. Their Care Team.
Platform insights are informed by the patient’s ecosytem. The platform products connect with 300+ consumer wearable devices and 940+ health systems and pharmacies.
A Remote Care Model that Supports the Patient Journey.
Flexible Integration Approach.
Access a flexible, scalable, easy-to-use platform that supports multiple chronic conditions and can integrate with your current systems through technology partnerships.
Access Patient Health Data.
Real-time care coordination requires real-time patient health data. Access patient information and recommended treatment modifications based on actual health trends and patterns. Get patient SMART Visit Reports containing clinical decision support for more productive care team visits.
Close Gaps in Care.
Proactively address gaps in care, care transitions and readmissions, and gain deeper insights into how patients are doing.
Achieve Better Population Health Insights.
The ability to collect and analyze patient health data allows providers to better coordinate care and support people throughout their care journeys.
CMS Reimbursement for Remote Patient Monitoring.
As an FDA-cleared software as a medical device (SaMD) for type 1 and type 2 diabetes, BlueStar is reimbursable by CMS for RPM services while allowing patients to use whatever hardware device they choose.
Clinical and Economic Analysis in Type 2 Diabetes.
12-Month Clinical Trial
In a prospective, randomized, controlled study, Quinn et al. (Diabetes Care, 2011) found that, individuals with type 2 diabetes whose A1C levels were > 7.5% at the time of enrollment, and who were randomized to use a mobile phone app to help them manage their diabetes in addition to usual care, improved A1C by an average 1.9%. Persons randomized to usual care alone improved A1C by an average of 0.7%. The difference between the intervention group and the control group was 1.2% (P < 0.001) over 12 months.
Methodology-Primary endpoint: change in A1C over one year. Randomization to one of four groups: (1) usual care (n=56), (2) usual care plus patient mobile app/access to web portal for diabetes management (n=23), (3) usual care, mobile app/portal for patient, plus provider access to raw patient data (n=22), and (4) usual care, mobile app/portal for patient, plus patient data tied to decision support for their physician (n=62). 213 patients enrolled; 163 included in the analysis. Limitations- Private insurance only. Study dropout rates required use of mixed-effects statistical modeling to impute missing observations
The Impact of A1C Reduction on Cost Savings.
Study Set Up
Welldoc funded a retrospective analysis with IBM Watson Health to test the relationship between A1C reduction and cost savings.
Data Inputs
IBM Watson Health was provided starting and ending A1C data from 3,000+ BlueStar users with type 2 diabetes.
Study Population
IBM Watson Health ran user data through their MarketScan Database, which captures claims data of more than 200 million individuals in the US.
Medical Expenditures Correlated with A1C Reduction.
Hospitalizations, ER visits, and HCP office visits
Cost of medical devices, supplies, and medications
Cost of comorbid conditions (hypertension, weight, etc.)
Reach At-Risk Populations. At Scale.
Scale up to address the health conditions of the most vulnerable populations, while enabling care teams to have direct communication with those most in need of intervention.
Drive Engagement and Satisfaction with Your Patients.
With increased consumerization in healthcare, organizations benefit from improving the patient experience. Let us boost your numbers.
